Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema

Area of Science:

• Ophthalmology
• Pharmacology
• Biomedical Engineering

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
• Current treatments for DME have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the safety and efficacy of novel 1.5% dexamethasone aqueous eye drops utilizing cyclodextrin microparticles for DME treatment.
• To assess the impact of these eye drops on visual acuity, central macular thickness, and intraocular pressure.

Main Methods:

• A pilot study involving 19 patients with DME.
• Patients received dexamethasone-cyclodextrin eye drops three or six times daily for 4 weeks, followed by a 4-week observation period.
• Key parameters including logMAR visual acuity, central macular thickness (CMT) via OCT, and intraocular pressure (IOP) were measured at baseline, week 4, and week 8.

Main Results:

• Significant improvements in visual acuity (logMAR) and reductions in CMT were observed at week 4 (P < 0.003) and week 8.
• At week 4, 63% of eyes showed >10% decrease in CMT, and 74% experienced >0.1 logMAR visual acuity improvement.
• No severe adverse effects were reported, indicating good tolerability.

Conclusions:

• Topical dexamethasone-cyclodextrin eye drops are safe and effective in reducing CMT and improving visual acuity in DME patients.
• These findings support further comparative studies of dexamethasone-cyclodextrin microparticle eye drops against established DME treatments.